2367 — Giant Biogene Holding Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeLarge CapHigh Flyer

Annual income statement for Giant Biogene Holding Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,190	1,552	2,364	3,524	5,539
Cost of Revenue
Gross Profit	1,007	1,354	1,995	2,947	4,547
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	217	580	1,187	1,779	3,077
Operating Profit	973	973	1,178	1,745	2,462
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	973	973	1,178	1,745	2,458
Provision for Income Taxes
Net Income After Taxes	826	828	1,002	1,448	2,062
Minority Interest
Net Income Before Extraordinary Items
Net Income	826	828	1,002	1,452	2,062
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	826	828	1,002	1,452	2,062
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.831	0.841	1.47	1.48	2.06
Dividends per Share
Special Dividends per Share